Lifeline Biotechnologies Inc
Lifeline Biotechnologies, Inc. operates as a medical technology company in the United States. Its technologies focus on prevention, early diagnosis, and quick recovery of various diseases. The company offers First Warning System, a non-invasive, non-compressive, and non-radiogenic device used in assisting the early discovery of breast tissue abnormalities in women. It also provides Mastascope, a … Read more
Lifeline Biotechnologies Inc (LLBO) - Net Assets
Latest net assets as of December 2009: $6.11 Million USD
Based on the latest financial reports, Lifeline Biotechnologies Inc (LLBO) has net assets worth $6.11 Million USD as of December 2009.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($6.72 Million) and total liabilities ($616.69K). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $6.11 Million |
| % of Total Assets | 90.83% |
| Annual Growth Rate | -15.3% |
| 5-Year Change | -99.1% |
| 10-Year Change | N/A |
| Growth Volatility | 47.54 |
Lifeline Biotechnologies Inc - Net Assets Trend (2003–2018)
This chart illustrates how Lifeline Biotechnologies Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Lifeline Biotechnologies Inc (2003–2018)
The table below shows the annual net assets of Lifeline Biotechnologies Inc from 2003 to 2018.
| Year | Net Assets | Change |
|---|---|---|
| 2018-12-31 | $55.20K | -44.01% |
| 2017-12-31 | $98.59K | +168.79% |
| 2016-12-31 | $-143.32K | +3.98% |
| 2015-12-31 | $-149.26K | -102.44% |
| 2009-12-31 | $6.11 Million | +1616.22% |
| 2004-12-31 | $-402.80K | -160.45% |
| 2003-12-31 | $666.38K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Lifeline Biotechnologies Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 459919500.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2018)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $31.39K | 56.86% |
| Other Comprehensive Income | $14.33 Million | 25951.98% |
| Total Equity | $55.20K | 100.00% |
Lifeline Biotechnologies Inc Competitors by Market Cap
The table below lists competitors of Lifeline Biotechnologies Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Gncc Capital Inc.
PINK:GNCP
|
$0.99 |
|
Praetorian Property Inc
PINK:PRRE
|
$0.99 |
|
Applied Visual Sciences Inc
PINK:APVS
|
$0.99 |
|
Liquid Holdings Group Inc
PINK:LIQDQ
|
$0.99 |
|
Azteca Gold Corp
PINK:AZGFF
|
$0.99 |
|
BPI Energy Holdings Inc
PINK:BPIGF
|
$0.98 |
|
Amcor Financial Corporation
OTCGREY:AFCL
|
$0.98 |
|
Falken Industries
PINK:FLKI
|
$0.98 |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Lifeline Biotechnologies Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2017 to 2018, total equity changed from 98,593 to 55,205, a change of -43,388 (-44.0%).
- Net loss of 43,388 reduced equity.
Equity Change Factors (2017 to 2018)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-43.39K | -78.59% |
| Total Change | $- | -44.01% |
Book Value vs Market Value Analysis
This analysis compares Lifeline Biotechnologies Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 5.69x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2015-12-31 | $0.00 | $0.00 | x |
| 2016-12-31 | $0.00 | $0.00 | x |
| 2017-12-31 | $0.00 | $0.00 | x |
| 2018-12-31 | $0.00 | $0.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Lifeline Biotechnologies Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -78.59%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 7.99x
- Recent ROE (-78.59%) is below the historical average (4.03%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2003 | -129.19% | -2940.45% | 0.03x | 1.58x | $-921.05K |
| 2004 | 0.00% | -1758.17% | 0.14x | 0.00x | $-1.70 Million |
| 2009 | -9.40% | 0.00% | 0.00x | 1.10x | $-1.18 Million |
| 2015 | 0.00% | 4.02% | 0.31x | 0.00x | $17.54K |
| 2016 | 0.00% | 9.89% | 0.19x | 0.00x | $20.27K |
| 2017 | 245.37% | 69.12% | 0.70x | 5.11x | $232.06K |
| 2018 | -78.59% | 0.00% | 0.00x | 7.99x | $-48.91K |
Industry Comparison
This section compares Lifeline Biotechnologies Inc's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $694,749,556
- Average return on equity (ROE) among peers: -25.46%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Lifeline Biotechnologies Inc (LLBO) | $6.11 Million | -129.19% | 0.10x | $0.99 |
| Advanced Biomedical Technologies Inc (ABMT) | $-4.46 Million | 0.00% | 0.00x | $14.18K |
| Abbott Laboratories (ABT) | $4.82 Billion | 39.04% | 1.31x | $191.37 Billion |
| Acarix AB (publ) (ACIXF) | $1.93 Million | -127.02% | 0.21x | $26.42 Million |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $-72.62 Million | 0.00% | 0.00x | $4.05 Million |
| Adm Tronics Unltd (ADMT) | $-12.69K | 0.00% | 0.00x | $3.17 Million |
| Aethlon Medical Inc (AEMD) | $-3.07 Million | 0.00% | 0.00x | $2.79 Million |
| Acutus Medical Inc (AFIB) | $126.58 Million | -80.56% | 0.52x | $732.88K |
| Adapthealth Corp (AHCO) | $2.07 Billion | 7.56% | 1.54x | $914.25 Million |
| Allied Healthcare Products Inc. (AHPIQ) | $8.88 Million | -33.95% | 1.22x | $726.24 |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $3.39 Million | -59.65% | 0.38x | $9.18 Million |